Open access
Jul 2026
Model-optimized bispecific antibodies improve the selectivity of antibody–drug conjugates for tumors
It is shown that with careful optimization, bispecific ADCs (bsADCs) can improve tumor selectivity, and a practical method of model-guided optimization of dual targeting, which may have broader applicability across antibody-based therapeutics is provided.
M. Stoddard, Sheetal K Panday, H. Gardner et al.
· Academia Drug Development an... · 0 citations